NSE ScannerAgri, Sugar & Edible Oils · Agricultural Commodities/Milling · NSE: INDOUS · data 2026-10-31
Indo US Bio-Tech Ltd.
In plain words
Price: 53.7% below its 52-week high of ₹159.
Delivery: 57.7% of traded shares were kept for delivery over the last 10 sessions, against 64.8% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹113 cr |
| Net profit (last 12 months) | ₹11 cr |
| Sales growth, 3 years (yearly) | 21.4% |
| Profit growth, 3 years (yearly) | 21.9% |
At a glance
Promoters 68.3% (-1.9 pts in a year), pledged 0.0%, institutions 0.3%.
P/E 12.9, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 15.3%, ROCE 18.8%, operating margin 12.9%: how much profit it earns on the money it uses.
Debt/equity 0.40, Profit growth 21.9% and sales growth 21.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 21.9% a year over 3 years.
- Promoters cut their holding by 1.9 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 40.6% over the last 20 sessions vs 67.8% in the 40 before (0.6x); shares delivered per day 1.45x usual; 3 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 3 Dec 24Dividend Dividend ₹0.25 (ex-date) -4.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 68.29% | 68.29% | 68.29% | 70.17% |
| Foreign institutions (FII) | 0.01% | 0.01% | 0.18% | — |
| Domestic institutions (DII) | 0.25% | — | — | — |
| Mutual funds | — | — | — | — |
| Retail investors | 8.38% | 8.85% | 8.74% | 7.92% |
| Number of shareholders | 4,629 | 4,690 | 4,531 | 4,738 |
Common questions
How much do promoters hold in Indo US Bio-Tech Ltd.?
Promoters held 68.29% of Indo US Bio-Tech Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Indo US Bio-Tech Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.4.
What is Indo US Bio-Tech Ltd.'s P/E ratio?
About 12.9, based on the last 12 months' earnings and a price of ₹73.54 (data 2026-10-31).
What is the 52-week high and low of Indo US Bio-Tech Ltd.?
The 52-week high is ₹159 and the 52-week low is ₹57.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Indo US Bio-Tech Ltd. | ₹73.54 | ₹148 cr | 12.9 | — | 15.3% | 18.8% | 0.4 | -48.0% |
| Dhunseri Tea & Industries Ltd | ₹143 | ₹151 cr | — | — | -0.5% | -3.4% | 0.48 | -12.8% |
| Mangalam Seeds Ltd | ₹130 | ₹151 cr | 17.1 | — | 9.8% | 13.5% | 0.56 | -6.1% |
| M K Proteins Limited | ₹3.69 | ₹148 cr | 29.5 | — | 9.4% | 15.1% | 0.49 | -45.7% |
| Dollex Agrotech Limited | ₹36.6 | ₹144 cr | 18.4 | — | 8.9% | 6% | 1.33 | -8.5% |
| B & A Limited | ₹375 | ₹128 cr | 159.3 | — | -2.8% | 2.7% | 0.81 | -14.6% |
Compare INDOUS with DTIL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INDOUS in NSE Scanner →